MaaT03X / MaaT Pharma - LARVOL DELTA

Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors (SITC 2023) - "MaaT03X conditioned medium further increased anti-PD-1 mediated T-cell activation, as evidenced by IFNγ release. Conclusions Altogether, these results highlight the potential of MaaT03X to restore gut barrier integrity and stimulate immune cell response to ICI therapy, with potential benefit for solid tumors treatment."

Checkpoint inhibition • Colon Cancer • Colorectal Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • GZMB • IFNG • IL2RA

MaaT Pharma Announces Poster Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Businesswire) - "MaaT Pharma...announced today that two abstracts have been accepted for poster presentations at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting, the world-leading event in immunotherapy, scheduled to be held from November 1-5, 2023, in San Diego, California, U.S.A. This is the first time that the Company will present non-clinical data in immuno-oncology which include its Artificial Intelligence (AI) screening approach and in vitro results for the first member of the new generation MaaT03X range of products dedicated to improving responses in immunotherapy for patients with solid tumors."

Preclinical • Solid Tumor